No effect of n-3 fatty acids supplementation on NT-proBNP after myocardial infarction: The Alpha Omega Trial

Abstract

Background

heart failure is a major risk factor for cardiovascular mortality, for which n-3 fatty acids may have beneficial effects. We examined the effect of marine eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and plant-derived alpha-linolenic acid (ALA) on N-Terminal-pro Brain Natriuretic Peptide (NT-proBNP), a biomarker of heart failure.

Methods

we randomly assigned 4837 post-myocardial infarction patients, aged 60–80 years (82% men), to margarines supplemented with a targeted additional intake of 400 mg/day EPA and DHA, 2 g/day ALA, EPA-DHA plus ALA, or placebo for 40 months. In a random selection of 639 patients, NT-proBNP was determined both at baseline and at the end of follow-up. NT-proBNP was log_e-transformed and analysed by type of treatment using analysis of covariance adjusting for baseline NT-proNBP.

Results

patients consumed on average 19.8 g margarine/day, providing an additional amount of 238 mg/day EPA with 158 mg/day DHA, 1.98 g/day ALA, or both, in the active-treatment groups. In the placebo group, the geometric mean level NT-proBNP increased from 245 ng/l (95%-confidence interval [CI]: 207–290) to 294 ng/l (95%-CI: 244–352) after 40 months (p = 0.001). NT-proBNP levels were not affected by ALA (+8% versus placebo; 95%-CI: −8% to +25%; p = 0.34), EPA-DHA (+2% versus placebo; 95%-CI: −14% to +18%; p = 0.78), nor EPA-DHA plus ALA (+9% versus placebo; 95%-CI: −8% to +25%; p = 0.31) treatment.

Conclusions

supplementation with modest amounts of EPA-DHA, with or without ALA, did not have a significant effect on NT-proBNP levels in patients with a history of myocardial infarction.

Keywords

n-3 Polyunsaturated fatty acids alpha-linolenic acid eicosapentaenoic acid docosahexaenoic acid NT-proBNP randomized double-blind placebo-controlled trial

Get full access to this article

View all access options for this article.

References

Djoussé

Akinkuolie

. Fish consumption, omega-3 fatty acids and risk of heart failure: A meta-analysis. Clin Nutr 2012; 31: 846–853.

Mozaffarian

Lemaitre

King

. Circulating long-chain ω-3 fatty acids and incidence of congestive heart failure in older adults: the cardiovascular health study: a cohort study. Ann Intern Med 2011; 155: 160–170.

Tavazzi

Maggioni

Marchioli

. on behalf of the GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double blind, placebo-controllled trial. Lancet 2008; 372: 1223–1230.

Chin

Gust

Nestel

. Marine oils dose-dependently inhibit vasoconstriction forearm resistance vessels in humans. Hypertension 1993; 21: 22–28.

Zhang

Wang

. Docosahexaenoic acid affects endothelial nitric oxide synthase in caveolae. Arch Biochem Biophys 2007; 466: 250–259.

Ciubotaru

Lee

Wander

. Dietary fish oil decreases C-reactive protein, interleukin-6, and triacylglycerol to HDL-cholesterol ratio in postmenopausal women on HRT. J Nutr Biochem 2003; 14: 513–521.

Abeywardena

Head

. Lonchain n-3 polyunsaturated fatty acids and blood vessel function. Cardiovasc Res 2001; 52: 361–371.

Zhao

Shao

Teng

. Effects of n-3 polyunsaturated fatty acid therapy on plasma inflammatory markers and N-terminal Pro-brain Natriuretic Peptide in elderly patients with chronic heart failure. J Int Med Res 2009; 37: 1831–1841.

Kromhout

Giltay

Geleijnse

. for the Alpha Omega Trial Group. n-3 Fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010; 363: 2015–2026.

10.

Rizos

Ntzani

Bika

. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012; 308: 1024–1033.

11.

Macchia

Levantesi

Franzosi

. Investigators GISSI-Prevenzione: Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids. Eur J Heart Fail 2005; 7: 904–909.

12.

Braunwald

. Biomakers in heart failure. N Engl J Med 2008; 358: 2148–2159.

13.

Troughton

Frampton

Yandle

. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126–1130.

14.

Pascual-Figal

Domingo

Casas

. Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients. Eur Heart J 2008; 29: 1011–1018.

15.

Geleijnse

Giltay

Schouten

. Alpha Omega Trial Group. Effect of low doses of n-3 fatty acids on cardiovascular diseases in 4,837 post-myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. Am Heart J 2010; 159: 539–546.

16.

Hoogeveen EK, Geleijnse MJ, Kromhout D, et al. No effect of n-3 fatty acids on high-sensitivity C-reactive protein after myocardial infarction: The Alpha Omega Trial. Eur J Prev Cardiol. Epub ahead of print 17 June 2013. DOI: 2047487313494295.

17.

Giltay

Geleijnse

Schouten

. High stability of markers of cardiovascular risk in blood samples. Clin Chem 2003; 49: 652–655.

18.

Inker

Schmid

Tighiouart

. for the CKD-EPI Investigators. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012; 367: 20–29.

19.

Grubb

Blirup-Jensen

Lindström

. IFCC Working Group on Standardisation of Cystatin C (WG-SCC). First certified reference material for cystatin C in human serum ERM-DA471/IFCC. Clin Chem Lab Med 2010; 48: 1619–1621.

20.

Levey

Coresh

Greene

. Chronic Kidney Disease Epidemiology Collaboration. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007; 53: 766–772.

21.

Knol

Groenwold

Grobbee

. P-values in baseline tables of randomised controlled trials are inappropriate but still common in high impact journals. Eur J Prev Cardiol 2012; 19: 231–232.

22.

Schou

Gustafsson

Kjaer

. Long-term clinical variation of NT-proBNP in stable chronic heart failure patients. Eur Heart J 2007; 28: 177–182.

23.

Chen

Wood

Krauser

. NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy. Eur Heart J 2006; 27: 839–845.

24.

Maisel

Mueller

Adams

. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008; 10: 824–839.

25.

van Kimmenade

Januzzi

JL Jr

Bakker

. Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J Am Coll Cardiol 2009; 53: 884–890.

26.

Linssen

Bakker

Voors

. N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. Eur Heart J 2010; 31: 120–127.

27.

Nowatzke

Cole

. Stability of N-terminal pro-brain natriuretic peptide after storage frozen for one year and after multiple freeze-thaw cycles. Clin Chem 2003; 49: 1560–1562.

28.

Cauliez

Guignery

Marinier

. Two-year stability of NT-proBNP in frozen samples using the Roche Elecsys system. Ann Clin Biochem 2008; 45: 318–319.

29.

Moertl

Hammer

Steiner

. Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study. Am Heart J 2011; 161: 915.e1–915.e9.

30.

Mähönen

Jula

Harald

. The validity of heart failure diagnoses obtained from administrative registers. Eur J Prev Cardiol 2013; 20: 254–259.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB